- 询价
- 2025年08月21日
14 年金牌会员
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 询价记录
- 技术资料
- 生长状态：
悬浮生长
- 器官来源：
骨髓
- 年限：
62 years
- 免疫类型：
IgA kappa (Recent tests for IgA, kappa have not detected the production of IgA; the cells are producing kappa light chain.)
- 细胞形态：
淋巴样
- 运输方式：
冻存运输
- 物种来源：
人
- 是否是肿瘤细胞：
1
- 细胞类型：
B淋巴细胞
- 相关疾病：
多发性骨髓瘤
- 库存：
大量
- ATCC Number：
CRL-9068™
| Designations: | NCI-H929 [H929] | ||
| Depositors: | National Cancer Institute | ||
| Isotype: | IgA kappa (Recent tests for IgA, kappa have not detected the production of IgA; the cells are producing kappa light chain.) | ||
| Biosafety Level: | 1 | ||
| Shipped: | frozen | ||
| Medium & Serum: | See Propagation | ||
| Growth Properties: | suspension | ||
| Organism: | Homo sapiens | ||
| Morphology: | lymphoblast |
||
| Source: | Organ: bone marrow Disease: plasmacytoma; myeloma Cell Type: B lymphocyte; |
||
| Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. | ||
| Receptors: | transferrin | ||
| Antigen Expression: | PCA-1; CD38 + | ||
| DNA Profile (STR): | Amelogenin: X CSF1PO: 11 D13S317: 12 D16S539: 9,13 D5S818: 11,12 D7S820: 10,12 THO1: 9.3 TPOX: 8,11 vWA: 14,15 |
||
| Cytogenetic Analysis: | Near tetraploid. Most copies of chromosome 8 have the 8q+ abnormality. | ||
| Age: | 62 years | ||
| Gender: | female | ||
| Ethnicity: | Caucasian | ||
| Comments: | This cell line was established from a malignant effusion in a patient with myeloma. The cells are positive for plasma cell antigen 1 (PCA-1), transferrin receptor, CD38 (T10), but are negative for HLA DR, CALLA and markers of early B cell development. They are negative for Epstein-Barr virus nuclear antigen (EBNA). The cells have a rearrangement of the c-myc proto oncogene and express c-myc RNA. There is also an activated ras allele. |
||
| Propagation: | ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: 2-mercaptoethanol to a final concentration of 0.05 mM; fetal bovine serum to a final concentration of 10%. Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C |
||
| Subculturing: | Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 4 X 10(5) viable cells/ml. Interval: Maintain cultures at cell concentrations between 5 X 10(5) and 1 X 10(6) viable cells/ml. Medium Renewal: 2 to 3 times per week |
||
| Preservation: | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
||
| Related Products: | Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001 recommended serum:ATCC 30-2020 |
||
| References: | 22372: Hollis GF, et al. Complex translocation disrupts c-myc regulation in a human plasma cell myeloma. Mol. Cell. Biol. 8: 124-129, 1988. PubMed: 3275865 23349: Gazdar AF, et al. Establishment and characterization of a human plasma cell myeloma culture having a rearranged cellular myc proto-oncogene. Blood 67: 1542-1549, 1986. PubMed: 2423157 23351: Ernst TJ, et al. Identification of a second transforming gene, rasn, in a human multiple myeloma line with a rearranged c-myc allele. Blood 72: 1163-1167, 1988. PubMed: 3048435 |
||
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
- 作者
- 内容
- 询问日期
技术资料暂无技术资料 索取技术资料
NCI-H929
询价
